ES2672693T3 - Método para el acondicionamiento y quimioselección combinadas en un único ciclo - Google Patents

Método para el acondicionamiento y quimioselección combinadas en un único ciclo Download PDF

Info

Publication number
ES2672693T3
ES2672693T3 ES12774246.8T ES12774246T ES2672693T3 ES 2672693 T3 ES2672693 T3 ES 2672693T3 ES 12774246 T ES12774246 T ES 12774246T ES 2672693 T3 ES2672693 T3 ES 2672693T3
Authority
ES
Spain
Prior art keywords
hprt
subject
deficient
cells
purine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12774246.8T
Other languages
English (en)
Spanish (es)
Inventor
Noriyuki Kasahara
Robert H. Schiestl
Katrin HACKE
Akos SZAKMARY
Gay M. CROOKS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California, San Diego
Original Assignee
University of California Berkeley
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California, San Diego filed Critical University of California Berkeley
Application granted granted Critical
Publication of ES2672693T3 publication Critical patent/ES2672693T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES12774246.8T 2011-04-20 2012-04-20 Método para el acondicionamiento y quimioselección combinadas en un único ciclo Active ES2672693T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161477440P 2011-04-20 2011-04-20
US201161477440P 2011-04-20
PCT/US2012/034586 WO2012145723A1 (en) 2011-04-20 2012-04-20 Method for combined conditioning and chemoselection in a single cycle

Publications (1)

Publication Number Publication Date
ES2672693T3 true ES2672693T3 (es) 2018-06-15

Family

ID=47041955

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12774246.8T Active ES2672693T3 (es) 2011-04-20 2012-04-20 Método para el acondicionamiento y quimioselección combinadas en un único ciclo

Country Status (11)

Country Link
US (1) US9439928B2 (enExample)
EP (3) EP2699247B1 (enExample)
JP (4) JP5997257B2 (enExample)
AU (3) AU2012245269B2 (enExample)
CA (1) CA2861440C (enExample)
DK (1) DK2699247T3 (enExample)
ES (1) ES2672693T3 (enExample)
PL (1) PL2699247T3 (enExample)
RU (2) RU2611396C2 (enExample)
TR (1) TR201808037T4 (enExample)
WO (1) WO2012145723A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2611396C2 (ru) * 2011-04-20 2017-02-21 Де Реджентс Оф Де Юниверсити Оф Калифорния Способ совместного кондиционирования и хемоселекции за один цикл
US9682106B2 (en) * 2011-04-20 2017-06-20 The Regents Of The University Of California Method for combined conditioning and chemoselection in a single cycle
US20170209447A1 (en) * 2014-08-07 2017-07-27 Nitor Therapeutics Use of PNP Inhibitor to Treat Relapse of Malignancy after Hematopoietic Stem Cell Transplant
US20180140606A1 (en) * 2016-11-18 2018-05-24 Calimmune, Inc. In Vivo Chemoselection with Low Dose Thioguanine
JP6783674B2 (ja) 2017-01-20 2020-11-11 株式会社日立ハイテク 自動分析装置、自動分析装置における廃液方法、及び、三方電磁弁
CA3070242A1 (en) * 2017-07-18 2019-01-24 Calimmune, Inc. Compositions and methods for treating beta-hemoglobinopathies
EP3654994B1 (en) * 2017-07-18 2022-12-28 CSL Behring Gene Therapy, Inc. A modulatable switch for selection of donor modified cells
WO2019074980A1 (en) * 2017-10-09 2019-04-18 Stowers Institute For Medical Research METHODS AND COMPOSITIONS FOR EXPANSION OF CELL POPULATION
EP3897831A1 (en) * 2018-12-23 2021-10-27 CSL Behring LLC Donor t-cells with kill switch
CN113518825A (zh) * 2018-12-23 2021-10-19 美国杰特贝林生物制品有限公司 Wiskott-aldrich综合征的造血干细胞基因疗法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965126A (en) 1996-03-25 1999-10-12 The Penn State Research Foundation use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
WO1997043900A1 (en) * 1996-05-24 1997-11-27 The President And Fellows Of Harvard College In vivo selection
AU7605796A (en) 1996-11-04 1998-05-29 Saint Jude Children's Research Hospital (in vivo) selection of primitive hematopoietic cells
DE69841058D1 (de) * 1997-11-14 2009-09-24 Gen Hospital Corp Behandlung von hämatologischen störungen
GB9904281D0 (en) * 1999-02-24 1999-04-21 Reneuron Ltd Transplantation
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
US20030032003A1 (en) * 2000-02-02 2003-02-13 Schiestl Robert H. In vivo selection
WO2002040049A2 (en) * 2000-11-14 2002-05-23 The General Hospital Corporation Blockade of t cell migration into epithelial gvhd target tissues
US7037900B2 (en) * 2001-10-12 2006-05-02 Supergen, Inc. Composition and method for treating graft-versus-host disease
RU2611396C2 (ru) * 2011-04-20 2017-02-21 Де Реджентс Оф Де Юниверсити Оф Калифорния Способ совместного кондиционирования и хемоселекции за один цикл

Also Published As

Publication number Publication date
EP3384912B1 (en) 2020-11-11
JP2018044007A (ja) 2018-03-22
HK1256048A1 (en) 2019-09-13
AU2012245269B2 (en) 2016-09-29
US9439928B2 (en) 2016-09-13
RU2017104621A (ru) 2018-08-15
TR201808037T4 (tr) 2018-06-21
AU2016259368A1 (en) 2016-12-08
RU2013151632A (ru) 2015-05-27
RU2611396C2 (ru) 2017-02-21
EP2699247A4 (en) 2014-11-19
JP6560332B2 (ja) 2019-08-14
AU2012245269A1 (en) 2013-12-05
EP2699247A1 (en) 2014-02-26
EP3799876A1 (en) 2021-04-07
AU2016259368B2 (en) 2017-12-14
EP3384912A1 (en) 2018-10-10
US20140154225A1 (en) 2014-06-05
JP5997257B2 (ja) 2016-09-28
EP2699247B1 (en) 2018-03-07
AU2018200967B2 (en) 2019-08-15
RU2017104621A3 (enExample) 2020-06-04
JP2014512391A (ja) 2014-05-22
DK2699247T3 (en) 2018-06-14
JP2019199476A (ja) 2019-11-21
JP2017008090A (ja) 2017-01-12
CA2861440A1 (en) 2012-10-26
CA2861440C (en) 2022-11-15
JP6799117B2 (ja) 2020-12-09
PL2699247T3 (pl) 2018-09-28
JP6266716B2 (ja) 2018-01-24
WO2012145723A1 (en) 2012-10-26
AU2018200967A1 (en) 2018-03-01
RU2728867C2 (ru) 2020-07-31

Similar Documents

Publication Publication Date Title
AU2018200967B2 (en) Method for combined conditioning and chemoselection in a single cycle
ES2940681T3 (es) Un interruptor modulable para la selección de células modificadas donantes
US11607427B2 (en) Method for chemoselection
Hacke et al. Combined preconditioning and in vivo chemoselection with 6-thioguanine alone achieves highly efficient reconstitution of normal hematopoiesis with HPRT-deficient bone marrow
HK1256048B (en) Method for combined conditioning and chemoselection in a single cycle
Wolf et al. Improved NK cell recovery following use of PTCy or Treg expanded donors in experimental MHC-matched allogeneic HSCT
US20240374569A1 (en) Hdac3 inhibitors for the treatment of langerhans cell histiocytosis and langerhans cell sarcoma
US20150342961A1 (en) Use of prostaglandin e1 (pge1) and misoprostol for treating chronic myelogenous/myeloid leukemia (cml)
Fooks Targeting Eukaryotic Initiation Factor 4A to Improve Response to Chemotherapy in Acute Myeloid Leukemia
Paul et al. 44. Novel Combination of megaTAL Nuclease-Driven Genome Engineering with a Drug Selection Cassette Increases Efficiency of HIV Gene Therapy